Non-steroidal antiandrogen monotherapy offers potential quality of life benefits over other treatment modalities in patients with prostate cancer. Nevertheless, gynecomastia and breast pain still represent the most bothersome side effects during this treatment. In this update article, recent advances in the management options for gynecomastia/breast pain caused by hormonal manipulation are reviewed and critically analyzed.
The profile of patients with prostate cancer has changed in recent years. Men are now being diagnosed at earlier stages of the disease and at a younger age. Consequently, they are still physically and sexually active and quality of life has become an important issue in their management. Hormonal therapies, which have a more favorable impact on quality of life than castration, are clearly required. Recent trials demonstrated that monotherapy with non-steroidal antiandrogens is effective and offers quality of life advantages over castration. Indeed, sexual interest and sexual function are both maintained to a greater extent than after castration in patients with prostate cancer after treatment with non-steroidal antiandrogens. 1, 2 The value of adding bicalutamide 150 mg daily to standard care for early prostate cancer (EPC) is being investigated in the bicalutamide EPC program. At a median follow-up of 5.4 years, the data analysis showed that bicalutamide reduces the risk of disease progression following radical prostatectomy or radiotherapy, in patients with locally advanced disease. 3 In general, non-steroidal antiandrogen monotherapy appears to be well tolerated in prostate cancer patients, with a predictable and manageable adverse event profile.
In the EPC program, the incidences of gynecomastia and breast pain were 66.2 and 72.8%, respectively, with symptoms developing in patient's majority within the first 6-9 months of bicalutamide therapy. Although these events were mostly mild and moderate, 15.6% of patients have been withdrawn from the EPC program owing to gynecomastia and/or breast pain. Of course, other adverse events (i.e., hot flushes, decreased libido, impotence) have been reported, but with a low incidence. 3 Gynecomastia in prostate cancer: where does it come from? Gynecomastia in males can result from physiological changes in growth and development or be caused pathologically, for instance, as chronic disease (e.g., chronic liver disease owing to alcohol abuse), tumor (e.g., choriocarcinoma). It can also be induced by drug treatments that affect the balance between estrogens and androgens, such as hormonal therapies for prostate cancer, 4 as summarized in Table 1 .
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Eliminating circulating testosterone by removing the primary source of testosterone or by blockade of LHRH receptors in the pituitary gland increases the ratio of estrogen to androgen and can lead to gynecomastia in patients with prostate cancer. Following orchiectomy, estradiol is produced by the peripheral aromatization of plasma androstenedione to estrone and subsequent conversion to estradiol. Estrogen treatment directly simulates the growth of mammalian tissue, resulting in severe gynecomastia. Both steroidal and non-steroidal antiandrogens block androgenic activity at the breast, thereby removing an inhibitory effect on estrogenic stimulation. Moreover, non-steroidal antiandrogens also blocks androgen receptors at a central level, inhibit the negative feedback effect of circulating testosterone, causing a reflex increase in levels of testosterone and leading to higher estrogen levels by peripheral aromatization. 4 Therefore, gynecomastia is caused by an increase in estrogenic activity relative to androgenic activity at the breast tissue (Figure 1 ).
Gynecomastia and its management: recent advances
Clinicians seeking treatment for prostate cancer need information on the management of gynecomastia and breast pain in their patients. In this respect, three options can be adopted: surgery, radiation therapy (RT) and medical therapy.
Surgery
A large number of surgical procedures have been described in the literature, including various types of techniques and incisions. Surgeons aim to reduce the breast size to normal contours, to eliminate painful tissue and to restore patient's chest to an acceptable cosmetic shape. Liposuction to remove excess fatty tissue has been used as an adjunct to surgery to remove glandular tissue. This combined approach enables a smooth chest profile to be obtained and has been associated with a low incidence of postoperative complications and high levels of patient satisfaction. The surgical liposuction has been utilized by Prezioso et al. 23 in a recent small study. Ten patients receiving hormone treatment for metastatic prostate cancer were selected if they had gynecomastia and breast pain. Five of them had been offered prophylactic RT before hormonal therapy, whereas the remaining patients have refused RT. The results were satisfactory in all patients, especially from an aesthetic point of view. At a follow-up of 6-36 months, only a few immediate postoperative complications were recorded. The authors conclude that surgical liposuction can be used for gynecomastia in very early stages and that the technique is simple and to be considered favorable, Another technique is represented by endoscopeassisted subcutaneous mastectomy and reconstruction (E-SMR), which has a longer operative time than SMR, but allows a drastically shorter incision, resulting in increased patient satisfaction. 24 
Radiation therapy
The most used treatment for gynecomastia is low-dose irradiation, particularly as a prophylaxis ( Table 2 ). The most extensive data are those from a randomized Scandinavian trial. 25 Patients with locally advanced non-metastasized PCa were treated with 3 months of neoadjuvant total androgen blockade. One arm was treated with RT to the breast before starting hormonal treatment. RT mostly with single fraction (12-15 Gy) was given to 174 (69%) of 253 evaluated patients. At the 1-year follow-up visit, some degree of gynecomastia was found in 71 and 28% (Po0.001) of non-irradiated and irradiated patients, respectively. The authors conclude that, with high significance, prophylactic RT of the breast decreases the risk of antiandrogen-induced gynecomastia and breast tenderness.
Tyrrell et al. 26 evaluated the efficacy and tolerability of prophylactic breast irradiation in reducing the incidence and severity of bicalutamide-induced gynecomastia and breast pain. Overall, 106 men with PCa and no current gynecomastia/breast pain were enrolled in this randomized, sham-controlled, double-blind, multicenter trial. Patients received either a single dose of electron beam RT (10 Gy) or sham RT. Bicalutamide 150 mg daily was administered for 12 months from the day of RT. The incidence of investigator-assessed gynecomastia was significantly lower with RT vs sham RT (52 vs 85%). Patients receiving RT experienced some breast pain reduction.
A comparative trial by Perdonà et al. 27 confirmed that prophylactic breast irradiation is an effective and welltolerated option in the management of bicalutamideinduced gynecomastia.
More recently, Van Poppel et al. 28 published the results from a multicenter trial including 51 patients receiving bicalutamide 150 mg daily for the treatment of nonmetastatic prostate cancer. Patients who developed symptomatic gynecomastia and/or breast pain received two 6 Gy fractions of external-beam RT. 72.5% patients experienced gynecomastia and 80.4% experienced breast pain, typically within the first 6 months. Twenty-seven and 38 patients, respectively, went on to receive breast irradiation. Following RT, gynecomastia improved or resolved in 25.9 and 7.4% cases, respectively, and breast pain improved or resolved in 31.6 and 7.9%, respectively.
Again, these positive findings have been confirmed in the same trial by Perdonà et al., 27 if you consider only the subgroup patients receiving RT as treatment. In all mentioned trials, RT-related adverse events (breast/ nipple erythema, skin irritation) resolved, were short in duration (median 3-5 weeks) and none was severe in intensity.
Medical therapy
Antiestrogens should improve gynecomastia by blocking estrogen receptors in targeted tissues. 29 Aromatase inhibitors should alleviate gynecomastia by preventing the peripheral aromatization of circulating androgens to estrogens. 30 In the last years, with the increasing use of bicalutamide in adjuvant setting, many trials have been published, focusing on the role of antiestrogens or aromatase inhibitors to reduce or prevent gynecomastia and/or breast pain in prostate cancer patients (Table 3) . It is to be noted that all these trials are randomized trials.
In the study by Eaton et al., 60 men starting primary hormonal manipulation for prostate cancer with bicalutamide 150 mg daily were randomized into two groups. Group 1 received tamoxifen 20 mg once weekly simultaneously with bicalutamide 150 mg daily. The control Group 2 received no treatment other than bicalutamide 150 mg daily. There was a significant reduction in breast pain (Po0.005) and enlargement (Po0.05) in Group 1. No difference in disease control as assessed by PSA values was found in the two groups. 31 Boccardo et al. 32 conducted a double-blind, placebocontrolled trial to determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide 150 mg, without compromising efficacy, safety or sexual functioning in prostate cancer patients. Patients were randomly assigned to either bicalutamide plus placebo or in combination with Gynecomastia and prostate cancer R Autorino et al tamoxifen (20 mg/day) or anastrozole (1 mg/day) for 48 weeks. Gynecomastia developed in 73% of patients in the bicalutamide group, 10% of patients in the bicalutamide-tamoxifen group and 51% in the bicalutamide-anastrozole group. However, the difference was significant only in respect to patients in the bicalutamide-tamoxifen group (Po0.001). Similarly, breast pain was more frequent and severe in patients in the bicalutamide group than in patients in either the bicalutamide-tamoxifen group or the bicalutamideanastrozole group; the difference was statistically significant only versus patients in the bicalutamidetamoxifen group (Po0.001). There was no major difference among groups in the proportion of patients achieving a X50% reduction in baseline PSA level. Overall treatments were well tolerated, with only 10, 11 and 14% of patients in the bicalutamide, bicalutamidetamoxifen and bicalutamide-anastrozole groups, respectively, experiencing serious adverse events. A similar randomized trial was published by Saltzstein et al. 33 This was a randomized double-blind, placebocontrolled, multicenter trial, involving 107 men receiving bicalutamide 150 daily following radical therapy for prostate cancer. This study assessed tamoxifen (20 mg/ day) and anastrozole (1 mg/day) for the prophylaxis and treatment of the gynecomastia/breast pain. Tamoxifen, but not anastrozole, significantly reduced the incidence of gynecomastia/breast pain when used prophylactically and therapeutically. No differences in PSA progression were observed.
We conducted the first randomized trial comparing the two different options (medical therapy and RT) in the treatment and prevention of bicalutamideinduced gynecomastia and breast pain in patients with prostate cancer during bicalutamide 150 mg monotherapy. 27 Patients were divided into three groups: Group 1 -receiving only bicalutamide 150 mg daily and those presenting a 3-4 score gynecomastia or moderate-severe breast pain successively randomized to receive tamoxifen 10 mg daily for 24 weeks or RT (single 12 Gy dose); Group 2 -treated with bicalutamide 150 mg daily and tamoxifen 10 mg daily for 24 weeks; Group 3 -treated with bicalutamide 150 mg daily and RT (single 12 Gy dose).
At 6 months, 35/51 patients (69%) developed gynecomastia in Group 1, compared with 4/50 patients (8%) in Group 2 and 17/50 patients (34%) in Group 3, these differences being statistically significant between Groups 1 and 2 (Po0.001) and Groups 1 and 3 (Po0.01). Breast pain was more frequent in Group 1 (29 patients) than in Group 2 (3 patients) and Group 3 (15 patients), these differences being again statistically significant between Groups 1 and 2 (Po0.001) and Groups 1 and 3 (Po0.025).
In Group 1, 35 patients developing gynecomastia and/ or breast pain were randomized to receive tamoxifen (17 patients) or RT (18 patients). A significant reduction of gynecomastia was obtained in patients receiving tamoxifen, whereas 10 out of 18 (56%) patients treated with RT still reported gynecomastia. There were no differences between the three groups as six (12%) PSA relapses occurred in Group 1, six (12%) in Group 2 and seven (13.7%) in Group 3.
Conclusions
The value of adding bicalutamide 150 mg daily to standard care for EPC is being investigated in the bicalutamide EPC program. This therapeutic option offers potential quality of life benefits over other treatment modalities. In general, non-steroidal antiandrogen monotherapy appears to be well tolerated in prostate cancer patients, with a predictable and manageable adverse event profile. However, gynecomastia and breast pain can occur.
These adverse events can be effectively and safely managed with different therapeutic options, as shown in several trials, most of them published in the last years, which represents a proof of the increasing interest in this PCa ¼ prostate carcinoma; pts. ¼ patients. *P significant between tamoxifen and placebo; P not significant between anastrazole and placebo. **P significant between tamoxifen and placebo; P significant between anastrazole and placebo about gynecomastia and breast pain.
Gynecomastia and prostate cancer R Autorino et al field. Of course, some points need to be clarified by further investigations:
1. There are some concerns about the use of antiestrogen therapy in prostate cancer, as tamoxifen could increase androgen secretion by blocking the negative feedback of estradiol on the hypothalamic-pituitary axis. Thus, clinical trials addressing this issue are needed. 2. The optimal schedule of antiestrogen therapy remains to be established. 3. Consensus is lacking about the optimal schedule and dosage of RT in this setting.
